An observational study in Bullous Pemphigoid, sponsored by University Hospital, Brest. Completed at 16 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-07.
Sponsored by University Hospital, Brest · Observational
Among 28 studies in Pemphigoid, Bullous with a site in France — 5 open to participants now, 6 under way, 1 of them phase 3. Pemphigoid, Bullous · France.
Among the 28 studies in Pemphigoid, Bullous with a site in France, this one is the 9th largest by enrollment of the 11 observational ones that give a count, is the only one that started in 2017, is one of 11 observational ones, and was the 11th registered.
64 studies on the registry are indexed under Pemphigoid, Bullous; 8 are open to participants now.
Browse Pemphigoid, Bullous studies →5 of the 28 studies in Pemphigoid, Bullous with a site in France are open now. Recruiting first, the newest first:
Chugai Pharmaceutical · Sites in France, United States, Australia and 17 more countries
Ages 18–85
University Hospital, Bordeaux · Sites in France
Ages 70+
CHU de Reims · Sites in France
Ages 18+
Chugai Pharmaceutical · Sites in France, Australia, Austria and 16 more countries
Ages 18–85
University Hospital, Rouen · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 5 Pemphigoid, Bullous studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 6 · Phase 4 2
First in 2001; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is below the median of 120 across 22 observational studies indexed under Pemphigoid, Bullous.
Median enrollment 67 across the 17 interventional studies, 122 across the 11 observational. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 28 have an industry lead sponsor. The 10 most frequent:
University Hospital, Brest is the lead sponsor of 601 studies on the registry; 136 are open to participants now.
University Hospital, Brest has 1 study filed under Pemphigoid, Bullous — fewer than ten, so there is no comparison to draw.
2 of the studies in Pemphigoid, Bullous with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03295383Phase 3University Hospital, RouenRandomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid | 2027-03 |
| NCT06371417Chugai PharmaceuticalPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies in Pemphigoid, Bullous with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Whereas pruritus is a major symptom in bullous pemphigoid, its characteristics and its impact on quality of life have been little studied.
The objective of this study is to learn more about pruritus characteristics of patients with bullous pemphigoid, and in consequence to better understand the pathophysiology of pruritus, and then to better treat pruritus in this condition.
All patients with a new diagnosis of bullous pemphigoid
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinical characteristics of pruritus in patients with bullous pemphigoid
Answers and scores in questionnaire about clinical characteristics of pruritus Demographics characteristics of patients Characteristics of the bullous pemphigoid
Time frame: Day1 ( when diagnosis of bullous pemphigoid is made)
Impact of pruritus on quality of life in patients with bullous pemphigoid
Score 5D itch scale
Time frame: Day 1 (when diagnosis of bullous pemphigoid is made )
Impact of pruritus on quality of life in patients with bullous pemphigoid
score ItchyQol (Itchy Quality of Life)
Time frame: Day1 (when diagnosis of bullous pemphigoid is made )
Impact of pruritus on quality of life in patients with bullous pemphigoid
score ABQOL
Time frame: Day 1 (when diagnosis of bullous pemphigoid is made )
Ran from Nov 2017 to primary completion in Oct 2018, 10 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.